Department of Intensive Care, CHU-Charleroi, Université Libre de Bruxelles, Charleroi, Belgium.
Crit Care Clin. 2012 Jul;28(3):345-62, v. doi: 10.1016/j.ccc.2012.04.003.
Anemia is common in critically ill patients, but treatment with red blood cell transfusions can have unwanted effects. Limiting the occurrence and severity of anemia by using erythropoietic agents (iron and/or recombinant erythropoietin), therefore, remains an attractive option during the intensive care unit stay but also after hospital discharge. Moreover, these agents may have additional beneficial properties. In this article the authors review the rationale for the administration of iron and/or erythropoietin in critically ill patients.
贫血在危重症患者中很常见，但红细胞输注治疗可能会产生不良影响。因此，在重症监护病房期间以及出院后，通过使用促红细胞生成剂（铁和/或重组红细胞生成素）来限制贫血的发生和严重程度仍然是一种有吸引力的选择。此外，这些药物可能具有额外的有益特性。本文作者回顾了在危重症患者中给予铁和/或红细胞生成素的基本原理。
